CliffBio
biologic

Brineura

cerliponase alfa

Loss of exclusivityApril 2029projected — 12-year biologic exclusivity estimate
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameBrineura
Active ingredientcerliponase alfa
Strength150MG/5ML (30MG/ML)
Dosage formInjection
RouteIntraventricular
ModalityBiologic
FDA approvalApril 2017
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.